Cargando…
Mouse models of uveal melanoma: Strengths, weaknesses, and future directions
Uveal melanoma is the most common primary malignancy of the eye, and a number of discoveries in the last decade have led to a more thorough molecular characterization of this cancer. However, the prognosis remains dismal for patients with metastases, and there is an urgent need to identify treatment...
Autores principales: | Richards, Jackson R., Yoo, Jae Hyuk, Shin, Donghan, Odelberg, Shannon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065156/ https://www.ncbi.nlm.nih.gov/pubmed/31880399 http://dx.doi.org/10.1111/pcmr.12853 |
Ejemplares similares
-
Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019) -
Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions
por: Brewington, Beatrice Y, et al.
Publicado: (2018) -
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions
por: Lamas, Nuno Jorge, et al.
Publicado: (2021) -
Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019) -
Strengths and weakness of neuroscientific investigations of childhood poverty: future directions
por: Lipina, Sebastián J., et al.
Publicado: (2015)